

**INTERNALLY FUNDED**

**EXTERNALLY FUNDED**

PRODUCT	INDICATION	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	PARTNER/COLLABORATOR/FUNDER
<b>COVID-19</b>						
INO-4800	COVID-19 (INNOVATE)*					
	COVID-19 (Solidarity)					
<b>INFECTIOUS DISEASES</b>						
INO-4700	MERS					CEPI
INO-4500	Lassa Fever					CEPI
INO-4201	Ebola (Booster)					
<b>HPV-TARGETED</b>						
VGX-3100	Precancerous Cervical Dysplasia (HSIL)					 (China; INOVIO maintains global rights)
	Precancerous Vulvar Dysplasia (HSIL)					
	Precancerous Anal Dysplasia (HSIL)					
INO-3107	Recurrent Respiratory Papillomatosis (RRP)					
<b>IMMUNO-ONCOLOGY</b>						
INO-5401	Glioblastoma Multiforme (GBM)					REGENERON
INO-5151	Prostate Cancer					
<b>dMAb™</b>						
INO-A002	COVID-19					
	Zika					BILL & MELINDA GATES foundation

\* Advaccine funding 50% of INNOVATE Phase 3 Clinical Trial